Walleye Trading
CRSP icon

Walleye Trading’s CRISPR Therapeutics CRSP Stock Holding History

Walleye Trading’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.4M Sell
50,400
-20,200
-29% -$1.07M ﹤0.01% 1600
2025
Q4 		$3.7M Sell
70,600
-27,000
-28% -$1.62M 0.01% 1475
2025
Q3 		$6.33M Sell
97,600
-51,500
-35% -$2.96M 0.01% 1133
2025
Q2 		$7.25M Buy
149,100
+77,800
+109% +$3.01M 0.01% 983
2025
Q1 		$2.43M Sell
71,300
-23,000
-24% -$975K 0.01% 1519
2024
Q4 		$3.71M Buy
94,300
+65,300
+225% +$3.08M 0.01% 1340
2024
Q3 		$1.36M Sell
29,000
-1,400
-5% -$71K ﹤0.01% 1923
2024
Q2 		$1.64M Sell
30,400
-23,200
-43% -$1.34M ﹤0.01% 1725
2024
Q1 		$3.65M Sell
53,600
-58,800
-52% -$4.21M 0.01% 1338
2023
Q4 		$7.04M Sell
112,400
-3,700
-3% -$205K 0.02% 1015
2023
Q3 		$5.27M Sell
116,100
-33,800
-23% -$1.75M 0.01% 1083
2023
Q2 		$8.42M Sell
149,900
-58,500
-28% -$3.32M 0.03% 658
2023
Q1 		$9.43M Sell
208,400
-114,500
-35% -$5.56M 0.02% 655
2022
Q4 		$13.1M Buy
322,900
+24,000
+8% +$1.27M 0.04% 524
2022
Q3 		$19.5M Buy
298,900
+131,000
+78% +$9.49M 0.06% 343
2022
Q2 		$10.2M Buy
167,900
+26,700
+19% +$1.57M 0.03% 591
2022
Q1 		$8.86M Buy
141,200
+92,500
+190% +$5.81M 0.03% 690
2021
Q4 		$3.69M Sell
48,700
-13,400
-22% -$1.17M 0.01% 1169
2021
Q3 		$6.95M Buy
62,100
+9,200
+17% +$1.16M 0.02% 744
2021
Q2 		$8.56M Sell
52,900
-2,400
-4% -$292K 0.03% 508
2021
Q1 		$6.74M Buy
55,300
+41,000
+287% +$6.19M 0.03% 499
2020
Q4 		$2.19M Buy
14,300
+2,400
+20% +$284K 0.01% 1325
2020
Q3 		$995K Buy
11,900
+300
+3% +$26.6K 0.01% 1649
2020
Q2 		$852K Sell
11,600
-8,400
-42% -$491K 0.01% 1807
2020
Q1 		$848K Sell
20,000
-25,900
-56% -$1.34M 0.01% 1427
2019
Q4 		$2.8M Buy
45,900
+31,000
+208% +$1.69M 0.02% 961
2019
Q3 		$611K Sell
14,900
-27,200
-65% -$1.3M 0.01% 1968
2019
Q2 		$1.98M Buy
42,100
+36,300
+626% +$1.45M 0.02% 1052
2019
Q1 		$207K Sell
5,800
-20,100
-78% -$695K ﹤0.01% 2997
2018
Q4 		$740K Buy
25,900
+22,900
+763% +$796K 0.01% 2050
2018
Q3 		$133K Buy
+3,000
New +$157K ﹤0.01% 4043

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Trading's CRSP Position: Q1 2026 in Review

Walleye Trading reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q1 2026, selling an estimated $138K and leaving 15,086 shares worth $718K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Walleye Trading first reported a position in CRSP in Q4 2018 and has held it in 12 quarters since. The position peaked at $1.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Walleye Trading held 15,086 shares of CRISPR Therapeutics worth $718K as of Q1 2026.
  • Walleye Trading sold 2,624 CRISPR Therapeutics shares in Q1 2026, an estimated $138K.
  • CRISPR Therapeutics made up ﹤0.01% of Walleye Trading's portfolio in Q1 2026, its #2353 holding.
  • Walleye Trading first reported a position in CRISPR Therapeutics in Q4 2018 and has held it in 12 quarters since.
  • Walleye Trading's CRISPR Therapeutics position peaked at $1.7M in Q2 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Walleye Trading's 13F filing for Q1 2026, filed 11 May 2026.